PMID- 26491283
OWN - NLM
STAT- MEDLINE
DCOM- 20160711
LR  - 20220310
IS  - 1178-2005 (Electronic)
IS  - 1176-9106 (Print)
IS  - 1176-9106 (Linking)
VI  - 10
DP  - 2015
TI  - Biomarker-based detection of asthma-COPD overlap syndrome in COPD populations.
PG  - 2169-76
LID - 10.2147/COPD.S88274 [doi]
AB  - Asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) was 
      proposed by the science committees of both Global Initiative for Asthma (GINA) 
      and Global Initiative for Chronic Obstructive Lung Disease (GOLD). However, the 
      definition of ACOS has remained unclear all over the world, and the prevalence 
      rate of ACOS is basically dependent on the patient's symptoms or the physician's 
      opinion, based on questionnaire testing. In the current case report, we 
      investigated the prevalence rate of COPD patients with high levels of fractional 
      exhaled nitric oxide (FENO) or immunoglobulin E (IgE) as candidate markers of 
      ACOS in COPD, as a multicenter, cross-sectional study. Outpatients with COPD were 
      enrolled from Tohoku University Hospital, Sendai, Japan, and five hospitals 
      (Tohoku University Hospital, Sendai, Japan; NTT East Tohoku Hospital, Sendai, 
      Japan; Wakayama Medical University Hospital, Kimiidera, Japan; Hiraka General 
      Hospital, Yokote, Japan; Iwate Prefectural Isawa Hospital, Oshu, Japan) with 
      pulmonary physicians from March 1, 2013 to February 28, 2014. When they were 
      estimated using 35 ppb as the cutoff value of FENO, the prevalence rate of ACOS 
      was 16.3% in COPD. When estimated by both FENO and IgE, the high-FENO/high-IgE 
      group was 7.8% in COPD. To the best of our knowledge, this study is the first to 
      detect the prevalence rate of ACOS in COPD populations by using objective 
      biomarkers. The results from the current study should be useful to identify the 
      subgroup requiring early intervention by inhaled corticosteroids/long-acting beta 
      agonist combination in COPD in order to improve the long-term management for 
      ACOS.
FAU - Tamada, Tsutomu
AU  - Tamada T
AD  - Department of Respiratory Medicine, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
FAU - Sugiura, Hisatoshi
AU  - Sugiura H
AD  - Department of Respiratory Medicine, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
FAU - Takahashi, Tsuneyuki
AU  - Takahashi T
AD  - Nippon Telegraph and Telephone East Corporation Tohoku Hospital, Sendai, Japan.
FAU - Matsunaga, Kazuto
AU  - Matsunaga K
AD  - Division of Respiratory Medicine and Infectious Disease, Graduate School of 
      Medicine, Yamaguchi University, Ube, Japan.
FAU - Kimura, Keiji
AU  - Kimura K
AD  - Hiraka General Hospital, Yokote, Japan.
FAU - Katsumata, Uichiro
AU  - Katsumata U
AD  - Iwate Prefectural Isawa Hospital, Oshu, Japan.
FAU - Takekoshi, Daisuke
AU  - Takekoshi D
AD  - Department of Respiratory Medicine, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
FAU - Kikuchi, Toshiaki
AU  - Kikuchi T
AD  - Department of Respiratory Medicine, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
FAU - Ohta, Ken
AU  - Ohta K
AD  - National Hospital Organization, Tokyo National Hospital, Kiyose, Tokyo, Japan.
FAU - Ichinose, Masakazu
AU  - Ichinose M
AD  - Department of Respiratory Medicine, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20151009
PL  - New Zealand
TA  - Int J Chron Obstruct Pulmon Dis
JT  - International journal of chronic obstructive pulmonary disease
JID - 101273481
RN  - 0 (Biomarkers)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Aged
MH  - *Asthma/diagnosis/epidemiology/metabolism/physiopathology
MH  - Biomarkers/analysis/metabolism
MH  - Breath Tests/methods
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - *Immunoglobulin E/analysis/metabolism
MH  - Japan/epidemiology
MH  - Male
MH  - *Nitric Oxide/analysis/metabolism
MH  - Prevalence
MH  - *Pulmonary Disease, Chronic 
      Obstructive/diagnosis/epidemiology/metabolism/physiopathology
MH  - *Pulmonary Elimination
MH  - Respiratory Function Tests/methods
MH  - Syndrome
PMC - PMC4608617
OTO - NOTNLM
OT  - FENO
OT  - ICS
OT  - IgE
OT  - LABA
OT  - airway inflammation
OT  - atopic factors
EDAT- 2015/10/23 06:00
MHDA- 2016/07/12 06:00
PMCR- 2015/10/09
CRDT- 2015/10/23 06:00
PHST- 2015/10/23 06:00 [entrez]
PHST- 2015/10/23 06:00 [pubmed]
PHST- 2016/07/12 06:00 [medline]
PHST- 2015/10/09 00:00 [pmc-release]
AID - copd-10-2169 [pii]
AID - 10.2147/COPD.S88274 [doi]
PST - epublish
SO  - Int J Chron Obstruct Pulmon Dis. 2015 Oct 9;10:2169-76. doi: 10.2147/COPD.S88274. 
      eCollection 2015.